

# Arvind Dasari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/130138/publications.pdf>

Version: 2024-02-01

76  
papers

5,641  
citations

236833

25  
h-index

82499

72  
g-index

76  
all docs

76  
docs citations

76  
times ranked

7096  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 34-42.	1.2	9
2	Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas. <i>Annals of Surgical Oncology</i> , 2022, 29, 2539-2548.	0.7	6
3	Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. <i>Oncologist</i> , 2022, 27, 299-306.	1.9	14
4	The immune impact of PI3K-AKT pathway inhibition in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 154-154.	0.8	2
5	Predictors and Outcomes of Minimally Invasive Surgery for Small Bowel Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1252-1265.	0.9	2
6	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	0.6	2
7	The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, 89-95.	1.0	10
8	Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2022, 8, 904.	3.4	13
9	The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Current Issues in Molecular Biology</i> , 2022, 44, 2015-2028.	1.0	5
10	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022, 5, e2213588.	2.8	10
11	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 137-147.e1.	1.0	17
12	Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, e53-e60.	1.0	24
13	Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 186-194.	0.9	17
14	Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	1.4	21
15	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. <i>JCO Oncology Practice</i> , 2021, 17, 607-614.	1.4	7
16	Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?. <i>Current Oncology Reports</i> , 2021, 23, 43.	1.8	131
17	Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. <i>Cancers</i> , 2021, 13, 1753.	1.7	33
18	Comprehensive Clinical and Molecular Characterization of <i>KRAS</i> <sup>G12C</sup> -Mutant Colorectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 613-621.	1.5	31

#	ARTICLE	IF	CITATIONS
19	Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. <i>Cancer Medicine</i> , 2021, 10, 4269-4281.	1.3	8
20	It's not a mystery, it's in the history: Multidisciplinary management of multiple endocrine neoplasia type 1. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 369-380.	157.7	4
21	The Provocative Roles of Platelets in Liver Disease and Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 643815.	1.3	10
22	Underreporting of race/ethnicity in COVID-19 research. <i>International Journal of Infectious Diseases</i> , 2021, 108, 419-421.	1.5	3
23	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 3151-3162.	1.1	14
24	Pharmacotherapy for unresectable metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, , 1-10.	0.9	1
25	Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. <i>Journal of Surgical Research</i> , 2021, 268, 419-431.	0.8	3
26	Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1893-1906.	2.0	7
27	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	0
28	Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2131744.	2.8	4
29	Report from American Society of Clinical Oncology Symposium 2020 and ASCO Gastrointestinal Cancer Symposium 2021. <i>Diseases of the Colon and Rectum</i> , 2021, Publish Ahead of Print, 8-10.	0.7	0
30	Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 507-511.	0.7	4
31	Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. <i>Cancer</i> , 2020, 126, 792-799.	2.0	22
32	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 48-56.e2.	1.0	2
33	Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms. <i>Current Treatment Options in Oncology</i> , 2020, 21, 96.	1.3	2
34	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa034.	1.4	59
35	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	1.0	3
36	Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. <i>British Journal of Cancer</i> , 2020, 122, 1309-1314.	2.9	77

#	ARTICLE	IF	CITATIONS
37	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal&#x201c;Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
38	Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4610-4610.	0.8	15
39	The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment (Review). <i>Oncology Letters</i> , 2019, 17, 4126-4132.	0.8	4
40	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , 2019, 121, 505-510.	2.9	32
41	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. <i>JAMA Oncology</i> , 2019, 5, e191870.	3.4	348
42	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , 2019, 125, 2732-2746.	2.0	19
43	Abdominal Manifestations of Neuroendocrine Tumors. <i>Digestive Disease Interventions</i> , 2019, 03, 014-029.	0.3	1
44	Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 1373-1379.	0.5	15
45	Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. <i>Oncologist</i> , 2019, 24, 1066-1075.	1.9	10
46	Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 510-513.	0.5	9
47	Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation?. <i>Diseases of the Colon and Rectum</i> , 2019, 62, 1158-1166.	0.7	74
48	Real&#x201c;World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. <i>Oncologist</i> , 2019, 24, 1056-1065.	1.9	8
49	Direct costs of carcinoid syndrome diarrhea among adults in the United States. <i>World Journal of Gastroenterology</i> , 2019, 25, 6857-6865.	1.4	7
50	Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. <i>Pharmacoeconomics</i> , 2018, 36, 1005-1013.	1.7	11
51	Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. <i>Annals of Surgical Oncology</i> , 2018, 25, 1709-1715.	0.7	32
52	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	3.2	225
53	Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. <i>Cancer</i> , 2018, 124, 807-815.	2.0	169
54	Circulating Tumor DNA&#x201c;Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. <i>Journal of Clinical Oncology</i> , 2018, 36, 3437-3440.	0.8	47

#	ARTICLE	IF	CITATIONS
55	Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. <i>Surgery</i> , 2017, 161, 753-759.	1.0	10
56	Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. <i>Lancet Oncology</i> , The, 2017, 18, 525-534.	5.1	271
57	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	3.2	50
58	Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. <i>JAMA Oncology</i> , 2017, 3, 1335.	3.4	2,289
59	Carcinoid heart disease. <i>Heart</i> , 2017, 103, 1488-1495.	1.2	56
60	Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. <i>Oncologist</i> , 2017, 22, 1451-1462.	1.9	20
61	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 155-163.	0.9	34
62	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0173345.	1.1	65
63	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 39268-39279.	0.8	69
64	Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. <i>Oncotarget</i> , 2017, 8, 99541-99551.	0.8	41
65	The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. <i>Oncologist</i> , 2016, 21, 563-570.	1.9	40
66	Update on management of midgut neuroendocrine tumors. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 175-189.	0.4	4
67	Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1966-1974.	0.9	60
68	High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. <i>Clinical Colorectal Cancer</i> , 2016, 15, e1-e7.	1.0	41
69	Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. <i>Oncologist</i> , 2016, 21, 308-313.	1.9	16
70	[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. <i>Future Oncology</i> , 2016, 12, 313-321.	1.1	3
71	Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i>-Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4032-4038.	0.8	583
72	Atypical Metastatic Presentations in Colorectal Cancer: A Case Series. <i>Clinical Colorectal Cancer</i> , 2014, 13, e1-e4.	1.0	9

#	ARTICLE	IF	CITATIONS
73	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 164-171.	1.0	108
74	Initial treatment of well-differentiated neuroendocrine tumors. <i>Oncology</i> , 2014, 28, 945-7.	0.4	1
75	A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. <i>Investigational New Drugs</i> , 2013, 31, 115-125.	1.2	46
76	Colorectal cancer during pregnancy or postpartum: Case series and literature review. <i>Obstetric Medicine</i> , 0, , 1753495X2110412.	0.5	4